Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter / Tate, Jillian R.

12 Issues per year


IMPACT FACTOR 2016: 3.432

CiteScore 2016: 2.21

SCImago Journal Rank (SJR) 2016: 1.000
Source Normalized Impact per Paper (SNIP) 2016: 1.112

Online
ISSN
1437-4331
See all formats and pricing
More options …
Volume 51, Issue 12 (Dec 2013)

Issues

Identification of an important potential confound in CSF AD studies: aliquot volume

Jamie Toombs
  • Corresponding author
  • Department of Molecular Neuroscience, Institute of Neurology, University College London, London, UK
  • Jamie Toombs and Ross W. Paterson contributed equally to this work.
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Ross W. Paterson
  • Corresponding author
  • Department of Neurodegeneration, Institute of Neurology, Dementia Research Centre, London, UK
  • Jamie Toombs and Ross W. Paterson contributed equally to this work.
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Michael P. Lunn / Jenifer M. Nicholas / Nick C. Fox / Miles D. Chapman / Jonathan M. Schott / Henrik Zetterberg
  • Department of Molecular Neuroscience, Institute of Neurology, University College London, London, UK
  • Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2013-08-12 | DOI: https://doi.org/10.1515/cclm-2013-0293

Abstract

Background: Cerebrospinal fluid (CSF) amyloid β1-42 (Aβ1-42), total tau (T-tau) and phosphorylated tau181 (P-tau) are finding increasing utility as biomarkers of Alzheimer’s disease (AD). The purpose of this study was to determine whether measured CSF biomarker concentrations were affected by aliquot storage volume and whether addition of detergent-containing buffer mitigates any observed effects.

Methods: AD and control CSF was distributed into polypropylene tubes in aliquots of different volumes (50–1500 μL). Aβ1-42, T-tau and P-tau were measured with and without addition of Tween 20 (0.05%).

Results: Measured concentrations of Aβ1-42 increased two-fold with aliquot storage volume. A volume increase of 10 µL caused an Aβ1-42 increase of 0.95 pg/mL [95% confidence interval (CI) 0.36–1.50, p=0.02] in controls, and 0.60 pg/mL (CI 0.23–0.98 pg/mL, p=0.003) in AD samples. Following addition of Tween 20, the positive relationship between Aβ1-42 and aliquot volume disappeared. T-tau and P-tau were not significantly affected.

Conclusions: CSF aliquot storage volume has a significant impact on the measured concentration of Aβ1-42. The introduction of a buffer detergent at the initial aliquoting stage may be an effective solution to this problem.

This article offers supplementary material which is provided at the end of the article.

Keywords: Alzheimer’s disease; amyloid β; cerebrospinal fluid; tau; volume

References

  • 1.

    Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010;6:131–44.CrossrefPubMedWeb of ScienceGoogle Scholar

  • 2.

    Bartlett JW, Frost C, Mattsson N, Skillback T, Blennow K, Zetterberg H, et al. Determining cut-points for Alzheimer’s disease biomarkers: statistical issues, methods and challenges. Biomark Med 2012;6:391–400.CrossrefWeb of ScienceGoogle Scholar

  • 3.

    Schoonenboom NS, Mulder C, Vanderstichele H, Van Elk EJ, Kok A, Van Kamp GJ, et al. Effects of processing and storage conditions on amyloid beta (1-42) and tau concentrations in cerebrospinal fluid: implications for use in clinical practice. Clin Chem 2005;51:189–95.Google Scholar

  • 4.

    Bateman RJ, Wen G, Morris JC, Holtzman DM. Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker. Neurology 2007;68:666–9.PubMedCrossrefGoogle Scholar

  • 5.

    Bjerke M, Portelius E, Minthon L, Wallin A, Anckarsater H, Anckarsater R, et al. Confounding factors influencing amyloid beta concentration in cerebrospinal fluid. Int J Alzheimers Dis 2010;2010:986310.PubMedGoogle Scholar

  • 6.

    Sjogren M, Vanderstichele H, Agren H, Zachrisson O, Edsbagge M, Wikkelso C, et al. Tau and Abeta42 in cerebrospinal fluid from healthy adults 21–93 years of age: establishment of reference values. Clin Chem 2001;47:1776–81.Google Scholar

  • 7.

    Perret-Liaudet A, Pelpel M, Tholance Y, Dumont B, Vanderstichele H, Zorzi W, et al. Cerebrospinal fluid collection tubes: a critical issue for Alzheimer disease diagnosis. Clin Chem 2012;58:787–9.CrossrefWeb of ScienceGoogle Scholar

  • 8.

    Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006;5:228–34.PubMedCrossrefGoogle Scholar

  • 9.

    Conversion and calculations Aqua-Calc. Available from: www.aqua-calc.com. Accessed 21 February, 2013.

  • 10.

    Wiltfang J, Esselmann H, Bibl M, Smirnov A, Otto M, Paul S, et al. Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer’s disease and in patients with chronic neuroinflammation. J Neurochem 2002;81:481–96.Google Scholar

  • 11.

    Bibl M, Esselmann H, Otto M, Lewczuk P, Cepek L, Ruther E, et al. Cerebrospinal fluid amyloid beta peptide patterns in Alzheimer’s disease patients and nondemented controls depend on sample pretreatment: indication of carrier-mediated epitope masking of amyloid beta peptides. Electrophoresis 2004;25:2912–8.PubMedCrossrefGoogle Scholar

  • 12.

    Kaiser E, Schonknecht P, Thomann PA, Hunt A, Schroder J. Influence of delayed CSF storage on concentrations of phospho-tau protein (181), total tau protein and beta-amyloid (1-42). Neurosci Lett 2007;417:193–5.Web of ScienceGoogle Scholar

  • 13.

    Carrillo MC, Blennow K, Soares H, Lewczuk P, Mattsson N, Oberoi P, et al. Global standardization measurement of cerebral spinal fluid for Alzheimer’s disease: an update from the Alzheimer’s Association Global Biomarkers Consortium. Alzheimers Dement 2013;9:137–40.CrossrefWeb of ScienceGoogle Scholar

About the article

Corresponding authors: Jamie Toombs, Department of Molecular Neuroscience, Institute of Neurology, University College London, London, UK, Phone: +44 20 34483553, E-mail: ; and Ross W. Paterson, Dementia Research Centre, Department of Neurodegeneration, Institute of Neurology, London, UK, Phone: +44 20 3448 3553, E-mail:


Received: 2013-04-17

Accepted: 2013-07-17

Published Online: 2013-08-12

Published in Print: 2013-12-01


Citation Information: Clinical Chemistry and Laboratory Medicine, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/cclm-2013-0293.

Export Citation

©2013 by Walter de Gruyter Berlin Boston. Copyright Clearance Center

Supplementary Article Materials

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Giovanni B. Frisoni, Daniela Perani, Stefano Bastianello, Gaetano Bernardi, Corinna Porteri, Marina Boccardi, Stefano F. Cappa, Marco Trabucchi, and Alessandro Padovani
Neurobiology of Aging, 2017, Volume 52, Page 119
[2]
Christelle Gervaise-Henry, Gasshan Watfa, Eliane Albuisson, Allan Kolodziej, Brigitte Dousset, Jean-Luc Olivier, Thérèse Rivasseau Jonveaux, and Catherine Malaplate-Armand
Journal of Alzheimer's Disease, 2017, Volume 57, Number 2, Page 437
[3]
Eline Willemse, Kees van Uffelen, Britta Brix, Sebastiaan Engelborghs, Hugo Vanderstichele, and Charlotte Teunissen
Alzheimer's & Dementia, 2017, Volume 13, Number 8, Page 885
[4]
Stephen P. Arnerić, Richard Batrla-Utermann, Laurel Beckett, Tobias Bittner, Kaj Blennow, Leslie Carter, Robert Dean, Sebastiaan Engelborghs, Just Genius, Mark Forrest Gordon, Janice Hitchcock, June Kaplow, Johan Luthman, Richard Meibach, David Raunig, Klaus Romero, Mahesh N. Samtani, Mary Savage, Leslie Shaw, Diane Stephenson, Robert M. Umek, Hugo Vanderstichele, Brian Willis, and Susan Yule
Journal of Alzheimer's Disease, 2016, Volume 55, Number 1, Page 19
[5]
Virginia Pérez-Grijalba, Noelia Fandos, Jesús Canudas, Daniel Insua, Diego Casabona, Ana M. Lacosta, María Montañés, Pedro Pesini, and Manuel Sarasa
Journal of Alzheimer's Disease, 2016, Volume 54, Number 2, Page 751
[6]
Hugo Marcel Johan Vanderstichele, Shorena Janelidze, Leentje Demeyer, Els Coart, Erik Stoops, Victor Herbst, Kimberley Mauroo, Britta Brix, Oskar Hansson, and Daniela Galimberti
Journal of Alzheimer's Disease, 2016, Volume 53, Number 3, Page 1121
[7]
Lauren M. Byrne and Edward J. Wild
Journal of Huntington's Disease, 2016, Volume 5, Number 1, Page 1
[8]
Guro Berge, Camilla Lauridsen, Sigrid Botne Sando, Daniel Joseph Holder, Ina Møller, Jan Olav Aasly, Geir Bråthen, Mary Josephine Savage, and Linda Rosemary White
Journal of Alzheimer's Disease, 2015, Volume 49, Number 2, Page 493
[9]
Jamie Toombs, Ross W. Paterson, Jennifer M. Nicholas, Axel Petzold, Jonathan M. Schott, and Henrik Zetterberg
Clinical Chemistry and Laboratory Medicine (CCLM), 2015, Volume 53, Number 12
[10]
Henrik Zetterberg
Current Opinion in Psychiatry, 2015, Volume 28, Number 5, Page 402
[11]
Ross W. Paterson, Jamie Toombs, Miles D. Chapman, Jennifer M. Nicholas, Amanda J. Heslegrave, Catherine F. Slattery, Alexander J.M. Foulkes, Camilla N. Clark, Christopher A.S. Lane, Philip S.J. Weston, Michael P. Lunn, Nick C. Fox, Henrik Zetterberg, and Jonathan M. Schott
Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 2015, Volume 1, Number 3, Page 380
[12]
Anthony Fourier, Erik Portelius, Henrik Zetterberg, Kaj Blennow, Isabelle Quadrio, and Armand Perret-Liaudet
Clinica Chimica Acta, 2015, Volume 449, Page 9
[13]
Mahlon A. Collins, Jiyan An, Danielle Peller, and Robert Bowser
Journal of Neuroscience Methods, 2015, Volume 251, Page 72
[14]
Sun Ah Park, Ju-Hee Kang, Eun-Suk Kang, Chang-Seok Ki, Jee Hoon Roh, Young Chul Youn, Seong Yoon Kim, and Sang Yun Kim
Journal of Clinical Neurology, 2015, Volume 11, Number 2, Page 132
[15]
Ross W. Paterson, Jamie Toombs, Catherine F. Slattery, Jonathan M. Schott, and Henrik Zetterberg
Molecular Diagnosis & Therapy, 2014, Volume 18, Number 2, Page 213

Comments (0)

Please log in or register to comment.
Log in